ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jiawei Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7934-5145; OpenAlex author ID A5090118088. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 2 papers

Papers 3

6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.jhazmat.2024.134790 ↗
PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer. Co-author DOI 10.1021/acs.est.4c08669 ↗
Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. First author DOI 10.1016/j.heliyon.2022.e12064 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shusen Zheng · 3 shared papers, 2022–2024 · strength 0.57
Linping Cao · 2 shared papers, 2024 · strength 0.39
- Paper 6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancre… DOI 10.1016/j.jhazmat.2024.134790 ↗
- Paper PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer. DOI 10.1021/acs.est.4c08669 ↗
Jun Qing Yu · 1 shared paper, 2024 · strength 0.20
- Paper 6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancre… DOI 10.1016/j.jhazmat.2024.134790 ↗
Wan-Wen Weng · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Donghai Jiang · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Kwabena Gyabaah Owusu-Ansah · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.